E
11.34
-0.57 (-4.79%)
| Previous Close | 11.91 |
| Open | 11.80 |
| Volume | 415,215 |
| Avg. Volume (3M) | 585,798 |
| Market Cap | 659,244,096 |
| Price / Earnings (TTM) | 11.45 |
| Price / Sales | 0.650 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| TTM Dividend Yield | 3.97% |
| Profit Margin | 5.25% |
| Operating Margin (TTM) | 21.42% |
| Diluted EPS (TTM) | 0.990 |
| Quarterly Revenue Growth (YOY) | -5.60% |
| Quarterly Earnings Growth (YOY) | -100.00% |
| Current Ratio (MRQ) | 2.24 |
| Operating Cash Flow (TTM) | 43.50 M |
| Levered Free Cash Flow (TTM) | -37.41 M |
| Return on Assets (TTM) | 3.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Mixed | |
| Stock | Embecta Corp. | Bearish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | -0.5 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 0.60 |
|
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 0.40% |
| % Held by Institutions | 98.48% |
| 52 Weeks Range | ||
| Median | 15.00 (32.28%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 10 Apr 2025 | 15.00 (32.28%) | Hold | 12.01 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Apr 2025 | Announcement | embecta to Report Fiscal Second Quarter 2025 Financial Results |
| 01 Apr 2025 | Announcement | Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations |
| 18 Feb 2025 | Announcement | embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference |
| 06 Feb 2025 | Announcement | Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results |
| 06 Feb 2025 | Announcement | embecta Announces Quarterly Cash Dividend |
| TTM Dividend Yield | 3.97% |
| 3Y Average Dividend Yield | 2.49% |
| Payout Ratio | 60.61% |
| Expected Next Dividend Payment | Jun 2025 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 06 Dec 2024 | 26 Nov 2024 | 18 Dec 2024 | 0.15 Cash |
| 27 Aug 2024 | 09 Aug 2024 | 13 Sep 2024 | 0.15 Cash |
| 24 May 2024 | 09 May 2024 | 14 Jun 2024 | 0.15 Cash |
| 27 Feb 2024 | 09 Feb 2024 | 15 Mar 2024 | 0.15 Cash |
| 01 Dec 2023 | 21 Nov 2023 | 15 Dec 2023 | 0.15 Cash |
| 24 Aug 2023 | 08 Aug 2023 | 13 Sep 2023 | 0.15 Cash |
| 25 May 2023 | 12 May 2023 | 13 Jun 2023 | 0.15 Cash |
| 24 Feb 2023 | 14 Feb 2023 | 13 Mar 2023 | 0.15 Cash |
| 29 Dec 2022 | 20 Dec 2022 | 11 Jan 2023 | 0.15 Cash |
| 25 Aug 2022 | 12 Aug 2022 | 14 Sep 2022 | 0.15 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 0.600 | 4 | 2.91 |
| 2023 | 0.750 | 5 | 3.96 |
| 2022 | 0.150 | 1 | 0.59 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |